European Commission mandates InferVision AI to monitor Covid-19 variants
Digitisation

European Commission mandates InferVision AI to monitor Covid-19 variants

InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus

  • By IPP Bureau | August 17, 2021

The European Commission has selected InferVision AI to monitor Covid-19 variants across the European Union. They have decided to increase their investment in the adoption of AI tools from InferVision.  The company has been working with the Commission since April 2020.

InferVision's AI applications have been developed to assist clinicians by quickly and accurately analyzing signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus. If these findings are present, an alert is provided immediately to staff allowing potential COVID-19 patients to be prioritized. The system also provides priors' comparison, allowing clinicians to monitor the progression of the disease over time, helping them to deliver better treatment plans.

Sun Yipeng, Director of InferVision Europe commented, "Many of us have lost loved ones in the pandemic. The medical world has devoted its resources to this critical effort and we are honoured to be able to provide advanced technology to help alleviate the workload at the frontlines. We believe that the use of AI in these efforts will serve to better mankind worldwide."

The selection process of the European Commission is based on three criteria: 1) technical excellence and the maturity of the technology, 2) the ability to make service available to the selected hospital quickly, and 3) feasibility of the proposed plan to install the system in the targeted number of hospitals. InferVision has fulfilled all criteria with high standards.

The European Commission has obtained useful information on the use of AI-powered image analytics in the context of the progression of the COVID-19 disease in the lungs, and the extension of the contract is expected to provide additional robust evidence on the benefits of the use of AI in healthcare.

Upcoming E-conference

Other Related stories

Startup

Digitization